These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31845983)

  • 1. Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding.
    Nicholls SJ
    Cardiovasc Res; 2020 Feb; 116(2):e30-e32. PubMed ID: 31845983
    [No Abstract]   [Full Text] [Related]  

  • 2. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 3. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine.
    Peterlin A; Petrovič D; Peterlin B
    Curr Vasc Pharmacol; 2019; 17(1):25-28. PubMed ID: 29412113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
    Khera AV; Rader DJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):195-201. PubMed ID: 20211435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy.
    Brown WV
    Clin Pharmacol Ther; 2018 Aug; 104(2):269-281. PubMed ID: 29998536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 9. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 10. Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.
    Hoffmann MM
    Curr Cardiol Rep; 2018 May; 20(7):56. PubMed ID: 29802474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in the Management of Dyslipidemia in a Clinical Practice Population at Very High Cardiovascular Risk. The COLIPAR Project.
    Cosín-Sales J; Gisbert-Criado R; Maceira AM; Buendía F; Gómez Ribelles R; Ruvira J
    Rev Esp Cardiol (Engl Ed); 2018 Nov; 71(11):979-980. PubMed ID: 29037611
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.
    Vanichakarn P; Hwa J; Stitham J
    Curr Mol Med; 2014; 14(7):849-79. PubMed ID: 25109793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
    Tsimikas S
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemias in clinical practice.
    Castro Cabezas M; Burggraaf B; Klop B
    Clin Chim Acta; 2018 Dec; 487():117-125. PubMed ID: 30201369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future".
    Sabouret P; Angoulvant D; Ray KK
    Arch Cardiovasc Dis; 2020 Mar; 113(3):147-151. PubMed ID: 32205042
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
    Jia X; Akeroyd JM; Nasir K; Nambi V; Ballantyne CM; Petersen LA; Virani SS
    Circulation; 2019 Mar; 139(10):1341-1343. PubMed ID: 30865483
    [No Abstract]   [Full Text] [Related]  

  • 18. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 19. Ezetimibe: rescued by randomization (clinical and mendelian).
    McPherson R; Hegele RA
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):e13-5. PubMed ID: 25550209
    [No Abstract]   [Full Text] [Related]  

  • 20. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.